Clinical Trials Sponsored by EVIVE Biotechnology

Total 1049 results

EVIVE Biotechnology

Withdrawn

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

COVID-19 Pneumonia
EVIVE Biotechnology

Completed

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
EVIVE Biotechnology

Completed

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
EVIVE Biotechnology

Completed

Trial to Compare the Efficacy and Safety of F-627 and GRAN® (F-627)

Breast Cancer

China
EVIVE Biotechnology

Terminated

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

Covid19

United States
EVIVE Biotechnology

Completed

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
EVIVE Biotechnology
Fudan University

Completed

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia
EVIVE Biotechnology
Memorial Sloan Kettering Cancer Center

Completed

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

Acute Graft vs Host Disease

United States
EVIVE Biotechnology
Peking University Cancer Hospital & Institute

Unknown

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma (A-319)

Relapsed or Refractory B-cell Lymphoma
EVIVE Biotechnology
Sun Yat-sen University; Fudan University

Completed

A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Neutropenia

China
Revive Therapeutics, Ltd.

Completed

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

Gout

United States
Revive Therapeutics, Ltd.

Terminated

Bucillamine in Treatment of Patients With COVID-19

Covid19

United States, Puerto Rico
Revive Therapeutics, Ltd.

Unknown

Bucillamine Phase 2 Trial in Patients With Cystinuria

Cystinuria

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Australia
Grit Biotechnology

Recruiting

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Adult

China
AVB Biotechnology

Recruiting

Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease (DoBiC-19)

Virus Diseases | COVID-19 | COVID-19 Pneumonia

Turkey
Grit Biotechnology

Recruiting

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Avecho Biotechnology

Not yet recruiting

Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia

Insomnia
Cellect Biotechnology

Unknown

Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

Acute Lymphoblastic Leukemia (ALL) | Hodgkin Lymphoma, Adult | Acute Myelogenous Leukemia (AML) | Non Hodgkin Lymphoma (NHL)

Israel
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Australia
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Melanoma

Australia, United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Study of PI-88 in Patients With Advanced Melanoma

Melanoma

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Terminated

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection (PATRON)

Cancer | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, Taiwan, Hong Kong, China
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Carcinoma, Hepatocellular

Taiwan
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) (GLEAM)

Systemic Lupus Erythematosus | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Lupus Erythematosus | SLE (Systemic Lupus) | Granulomatous Polyangiitis

United States
Grit Biotechnology

Recruiting

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Adult | Gynecological Tumors

China
Grit Biotechnology

Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

Solid Tumor, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

Solid Tumor | Adult | GT316

China
Grit Biotechnology

Recruiting

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Adult

China
Grit Biotechnology

Recruiting

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Solid Tumor

China
DynamiCure Biotechnology

Terminated

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
University of Alberta
Revive Wellness Inc.

Recruiting

Digital Metabolic Rehabilitation COPD

Chronic Obstructive Pulmonary Disease | Metabolic Syndrome

Canada
University of Alberta
Revive Wellness Inc.

Recruiting

A Web-based Platform to Improve Physical Function, Nutrition, and Mindfulness in Patients With Long COVID (BLEND)

Long COVID

Canada
Sana Biotechnology

Not yet recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma
Grit Biotechnology

Not yet recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Adult

China
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Australia
DynamiCure Biotechnology

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Australia
Grit Biotechnology

Recruiting

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (GT201)

Solid Tumor

China
Maia Biotechnology

Recruiting

THIO Sequenced With Cemiplimab in Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

Poland, Australia, Bulgaria, Hungary
Cellect Biotechnology

Unknown

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

Hematological Malignancies

Israel
University of Wisconsin, Madison
Revive Therapeutics, Ltd.

Recruiting

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Substance-Related Disorders | Chemically-Induced Disorders | Substance Use Disorders | Methamphetamine Use Disorder | Stimulant-Use Disorder

United States
Puma Biotechnology, Inc.

Recruiting

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer (ALISCA-Lung1)

Small Cell Lung Cancer

United States
TWi Biotechnology, Inc.

Recruiting

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

United States, Taiwan, Australia, Philippines
BiomeHub Biotechnology Company

Not yet recruiting

Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects

Glucose Metabolism Disorders | Diabetes | Health Behavior | Metabolic Disease
BRIM Biotechnology Inc.

Not yet recruiting

Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Neurotrophic Keratitis
Accutar Biotechnology Inc

Recruiting

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Vir Biotechnology, Inc.

Recruiting

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (MARCH)

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, Malaysia, New Zealand, Taiwan, United Kingdom, Romania, United States, Moldova, Republic of, Canada, Germany, Ukraine

Clinical Trials Sponsored by EVIVE Biotechnology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations